Twitxy Saved

Sara Coca Membribes

@scocmem

🧩 Medical Oncologist | #GUOncology Clinical Research Fellow |📍Barts Cancer Institute @BartsECMC @QMBCI
292 Following 568 Followers 1.2K Posts

Latest posts 5

Sara Coca Membribes @scocmem
Bispecifics now moving into the perioperative setting in NSCLC with encouraging pCR rate

Combinations with EV are being explored in first line mUC. Interesting to see whether these results can be achieved in UC.

nature.com/articles/s4159…

@OncoAlert
www.nature.com Perioperative ivonescimab with or without chemotherapy in resectable non-small cell lung cancer: a... Nature Medicine - In a nonrandomized phase 2 trial, patients with resectable non-small cell lung cancer received perioperative ivonescimab as monotherapy or with chemotherapy, leading to...
Hidehito HORINOUCHI Verified account @HHorinouchi 4d
🔥Perioperative ivonescimab ± chemo in resectable NSCLC
🆙 @NatureMedicine
🎯Primary endpoint met
🎯Cohort 2 (ivonescimab + chemo): MPR 70.1% (47/67), pCR 50.7% (34/67), RVT≤5% 97.9% (46/47)
🎯Cohort 1 (monotherapy) MPR 60.0% (6/10), pCR 30.0% (3/10), RVT≤5% 83.3% (5/6)
🎯All patients who underwent surgery achieved R0
🎯Grade ≥3 TRAEs 30.4%; no grade ≥3 hemorrhage or treatment-related death
🎙Dr. Xiaoliang Zhao
#LCSM @OncoAlert @Larvol
nature.com/articles/s4159…
View quoted post on X
Sara Coca Membribes @scocmem
Can’t help but love this one on ADCs!

A simple SOS framework from Team 🇨🇳

#UromigosLive @OncoAlert @yao_zhu_sh
Uromigos Verified account @Uromigos 3d
🇨🇳 Team China is sending a message: They're coming for the Uromigos World Cup! ⚽🏆

With Shanghai's Oriental Pearl Tower as their backdrop, they're tackling three of the biggest questions in ADC therapy: Selection, Overcoming Resistance, and Sequencing.

The race for the cup is heating up! 🔥

🎥 : @yao_zhu_sh & Xiaojie Bian | #UromigosLive
View quoted post on X
Sara Coca Membribes @scocmem
Particularly encouraging to see ongoing responses in such a heavily pretreated population (even after HIF-2a inhibitors and multiple VEGFR-TKIs)

And as @montypal highlighted, XmAb819 is also being evaluated in papillary RCC 👇

xencor.com/pipeline/xmab8…

@OncoAlert
Niklas Klümper Verified account @niklas_kluemper 4d
🚀 Could T-cell engagers open the next chapter in kidney cancer?

After disappointing phase III results with several IO/TKI/ HIF2a triplet strategies, we urgently need new mechanisms of action—not just more drugs!

Exciting phase I data for XmAb819, an ENPP3×CD3 bispecific T-cell engager in heavily pretreated ccRCC @montypal

🎯 Confirmed ORR: 45.5% (5/11) at the selected 400 µg/kg dose
🎯 35% ORR even after prior IO, VEGFR-TKI and HIF-2α inhibition

A fascinating approach: redirecting T cells directly against ENPP3-expressing tumor cells.

Could T-cell redirection become the next therapeutic pillar in RCC? 🔬

urotoday.com/conference-hig…

@OncoAlert @weoncologists @urotoday @Uromigos

@OncoAlert and Faculty: @DrChoueiri @tompowles1 @apolo_andrea @neerajaiims @montypal @Silke_Gillessen @AOmlin @brian_rini @PGrivasMDPhD @TiansterZhang @amerseburger @DrDanielHeng @HHammersMD @scocmem @AndreaNecchi @AmandaNizamMD @drenriquegrande @nataliagandur @AlbigesL @cdanicas @declangmurphy @seanmmcbride @shilpaonc @DrRanaMcKay @scserendipity1 @DrYukselUrun @ravikanesvaran @BraunMDPhD @EfstathiouEleni @mzugman @crisbergerot @Markuseckstein3
View quoted post on X